

31. (New) The method of claim 30 wherein the serum concentration of relaxin is maintained for a period of up to at least 72 hours.

32. (New) The method of claim 31 wherein relaxin is administered from an osmotic pump.

33. (New) The method of claim 32, wherein the osmotic pump is a multi-chamber osmotic pump system.

34. (New) The method of claim 29, wherein the predetermined rate comprises sequentially timed dispensing from an osmotic pump.

35. (New) The method of claim 28, wherein the administering is at a progressively diminishing rate.

#### REMARKS

Claims 23-35 are now pending in this application.

Original claims 1-22 have been canceled and new claims 23-35 have been added to more particularly point out and distinctly claim the invention. No new matter has been added.

New claims 23-27 correspond largely to allowed claims 28-32 within the parent application Serial No. 08/698,359 which claims have been allowed. New claim 23 is directed to a method of treatment as opposed to the specific method of promoting angiogenesis claimed within allowed claim 28 of the parent application. The dependent claims 24-27 are identical to the allowed claims 29-32 except for the numbering and their being dependent on different claims.

New claims 28-35 are supported within the originally filed application such as within Example 3 on pages 10-11 of the original specification. Example 3 clearly shows that recombinant human relaxin can be administered over time in a manner so as to induce secretion of vascular endothelial growth factor (VEGF). The specific number limitations within claims 30 and 31 are supported in the specification at page 11, lines 4 and 6 respectively. Dependent claims 32-35 are identical to allowed claims 29-32 of the parent application except for the numbering and the fact that these claims are dependent on different claims. No new matter has been added.

In the event any fees are due in connection with the filing of this preliminary amendment or attached application or if petitions are required, applicants petition for any required relief and authorize the Commissioner to charge the cost of such petitions or other fees to our Deposit Account No. 50-0815.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: Feb 4, 2001

By: Karl Bozicevic

Karl Bozicevic  
Registration No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, California 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231  
F:\DOCUMENT\CONN\003con\Amendment - Preliminary.rtf